Select area to zoom
Created with Highcharts 11.1.0Jul '24Oct '24Jan '25Apr '2550.0036.59

Profile

Edit
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
URL https://www.legendbiotech.com
Investor Relations URL https://investors.legendbiotech.com/
HQ State/Province New Jersey
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 08, 2025 (est.)
Last Earnings Release May. 13, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Edit
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
URL https://www.legendbiotech.com
Investor Relations URL https://investors.legendbiotech.com/
HQ State/Province New Jersey
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 08, 2025 (est.)
Last Earnings Release May. 13, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A
Quickflows